Evidence map›Paper›PMID 30983335›Full record

ArticleJournal of the American Chemical Society2019

Methylated Histidines Alter Tautomeric Preferences that Influence the Rates of Cu Nitrite Reductase Catalysis in Designed Peptides.

Karl J Koebke, Fangting Yu, Casey Van Stappen, Tyler B J Pinter, Aniruddha Deb, James E Penner-Hahn, Vincent L Pecoraro

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Design of the elusive proteinaceous oxygen donor copper site suggests a promising future for copper for MRI contrast agents.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. Article
  12. Catalysis and Electron Transfer inChemical reviews · 2022
    Review
  13. De novo metalloprotein design.Nature reviews. Chemistry · 2022
    Article
  14. Nitrite reductase activity within an antiparallel de novo scaffold.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021
    Article
  15. Article
  16. Catalysis and Electron Transfer in De Novo Designed Helical Scaffolds.Angewandte Chemie (International ed. in English) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Karl J KoebkeDepartment of Chemistry , University of Michigan , Ann Arbor , Michigan 48109 , United States.ORCID 0000-0003-2198-2667
Fangting YuDepartment of Chemistry , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Casey Van StappenDepartment of Chemistry , University of Michigan , Ann Arbor , Michigan 48109 , United States.ORCID 0000-0002-1770-2231
Tyler B J PinterDepartment of Chemistry , University of Michigan , Ann Arbor , Michigan 48109 , United States.ORCID 0000-0003-4381-3303
Aniruddha DebDepartment of Chemistry , University of Michigan , Ann Arbor , Michigan 48109 , United States.ORCID 0000-0002-0331-9709
James E Penner-HahnDepartment of Chemistry , University of Michigan , Ann Arbor , Michigan 48109 , United States.ORCID 0000-0003-0314-1274
Vincent L PecoraroDepartment of Chemistry , University of Michigan , Ann Arbor , Michigan 48109 , United States.ORCID 0000-0002-1540-5735
University of Michigan · US

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Toxic Metal Complexation By de Novo Designed PeptidesR01ES012236 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PECORARO, VINCENT L · 2003 to 2018
$4.4M
NIEHS NIH HHS R01 ES012236NIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

Copper proteins have the capacity to serve as both redox active catalysts and purely electron transfer centers. A longstanding question in this field is how the function of histidine ligated Cu centers are modulated by δ vs ε-nitrogen ligation of the imidazole. Evaluating the impact of these coordination modes on structure and function by comparative analysis of deposited crystal structures is confounded by factors such as differing protein folds and disparate secondary coordination spheres that make direct comparison of these isomers difficult. Here, we present a series of de novo designed proteins using the noncanonical amino acids 1-methyl-histidine and 3-methyl-histidine to create Cu nitrite reductases where δ- or ε-nitrogen ligation is enforced by the opposite nitrogen's methylation as a means of directly comparing these two ligation states in the same protein fold. We find that ε-nitrogen ligation allows for a better nitrite reduction catalyst, displaying 2 orders of magnitude higher activity than the δ-nitrogen ligated construct. Methylation of the δ nitrogen, combined with a secondary sphere mutation we have previously published, has produced a new record for efficiency within a homogeneous aqueous system, improving by 1 order of magnitude the previously published most efficient construct. Furthermore, we have measured Michaelis-Menten kinetics on these highly active constructs, revealing that the remaining barriers to matching the catalytic efficiency ( k

Indexed as

BiocatalysisCopperHistidineIsomerismMethylationModels, MolecularNitrite ReductasesOligopeptidesProtein BindingProtein Structure, SecondarySubstrate SpecificityCopperHistidineNitrite ReductasesOligopeptides

Identifiers

PMID30983335
PMCPMC6824201
OpenAlexW2939061017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.